Hazlett, Burt & Watson, Inc. Viking Therapeutics, Inc. Transaction History
Hazlett, Burt & Watson, Inc.
- $217 Million
- Q3 2024
A detailed history of Hazlett, Burt & Watson, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Hazlett, Burt & Watson, Inc. holds 70 shares of VKTX stock, worth $5,101. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70
Previous 70
-0.0%
Holding current value
$5,101
Previous $4,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
462Shares Held
65.9MCall Options Held
6.24MPut Options Held
2.97M-
Vanguard Group Inc Valley Forge, PA10.1MShares$736 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$439 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$373 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$164 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$135 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $5.59B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...